Gene vector
A gene vector comprising a miRNA sequence target.
1. A method comprising delivering a gene vector that comprises at least one miRNA target sequence operably linked to a transgene to:
(i) a cell that comprises a corresponding miRNA,
wherein in said cell expression of the transgene is prevented or reduced; and
(ii) a cell that does not comprise a corresponding miRNA, wherein in said cell the transgene is expressed,
wherein the transgene is a therapeutic gene.
2. A method comprising delivering a gene vector that comprises a transgene operably linked to at least one miRNA target sequence to:
(i) a cell that comprises a corresponding miRNA, thereby preventing immune mediated rejection of the transgene; and
(ii) a cell that does not comprise a corresponding miRNA, wherein in said cell the transgene is expressed, wherein the transgene is a therapeutic gene.
3. A method for preventing immune-mediated rejection according to claim 2 wherein the transferred gene is a circulating antigen.
4. A method of controlling transgene expression comprising delivering a gene vector that comprises at least one miRNA target sequence operably linked to the transgene to a cell that comprises a corresponding miRNA, wherein in said cell the transgene expression is prevented or reduced, and wherein the transgene is a therapeutic gene.
5. The method of claim 4 , wherein the method further comprises delivering the gene vector to a cell that does not comprise a corresponding miRNA, wherein in said cell the transgene is expressed.
6. The method of claim 4 , wherein the prevention or reduction of transgene expression in the cell comprising the corresponding miRNA prevents or reduces a detrimental effect to a subject caused by expression of the transgene in said cell.
7. The method of claim 6 , wherein the detrimental effect is an immune response to the transgene.
8. A method of de-targeting transgene expression from a type of cell in a subject comprising delivering a gene vector that comprises at least one miRNA target sequence operably linked to the transgene to the subject, wherein upon transduction of a cell that comprises a corresponding miRNA by the gene vector, expression of the transgene is prevented or reduced in said cell, and wherein the transgene is a therapeutic gene.
9. The method of claim 8 , wherein upon transduction of a cell that does not comprise a corresponding miRNA by the gene vector, the transgene is expressed in said cell.
10. The method of claim 8 , wherein the prevention or reduction of transgene expression in the cell comprising the corresponding miRNA prevents or reduces a detrimental effect to the subject caused by expression of the transgene in said cell.
11. The method of claim 10 , wherein the detrimental effect is an immune response to the transgene.
12. A method of controlling transgene expression comprising delivering a gene vector that comprises at least one miRNA target sequence operably linked to a transgene to
a cell that comprises a corresponding miRNA wherein in said cell expression of the transgene is prevented or reduced; and wherein the transgene is a toxic or suicide gene.